TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, attends BIO International Convention during 6/3~6/6 and will be in Taiwan Pavilon (Booth: 1917).

ImmunAdd developed a synthetic saponin IA-05 which can be synthesized in large scale and manufactured in GMP facility. IA-05 is formulated in aqueous solution or in liposome, and can act as adjuvant solely or with other adjuvants. IA-05 has been broadly evaluated in various vaccines by our collaborators, including worldwide vaccine companies, chemical and biologics companies, and academic research teams. IA-05 shows equivalent adjuvant activity as QS-21 does, and safer. ImmunAdd is now seeking for partnership to co-develop innovative and practical pharmaceutics for better health.

“While we are progressing our vaccine adjuvant candidate, IA-05, we are excited to share preclinical data on other approaches we are pursuing with the Biotech community” said Pi-Hui Liang, PhD, CEO of ImmunAdd. “We extend our sincere gratitude to the National Science and Technology Council (NSTC) for their invaluable support in enabling ImmunAdd’s participation at the US BIO exhibition. This opportunity has empowered us to showcase our products on the global stage, fostering enhanced market reach and driving accelerated product development. The NSTC’s backing has been instrumental in propelling our growth trajectory and bolstering our competitive edge in the international arena.”, said by Dr. Chun-Kai Chang, the director of vaccine at ImmunAdd.

ImmunAdd, Inc. is a privately held biopharmaceutical company which was founded in 2022 on a mission to improve health through advances in vaccine adjuvants, new formulation, and new drug design. The company is developing next generation saponin adjuvants, new combination of adjuvants and adjuvanted vaccines.

“Innovation for Better Health”

We are ImmunAdd.